SPRB Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

0.00

-100%

-12.310

-21.84%

-5.440

-87.27%

0.000

-100%

Estimates Revision

The market is revising No Change the revenue expectations for Spruce Biosciences, Inc. (SPRB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -53.92%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+8.27%

In Past 3 Month

Stock Price

Go Down

-53.92%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast SPRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPRB is 209.50 USD with a low forecast of 160.00 USD and a high forecast of 259.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

160.00

Averages

209.50

High

259.00

Current: 0.000

Low

160.00

Averages

209.50

High

259.00

H.C. Wainwright

initiated

$220

2025-12-22

Reason

H.C. Wainwright

Price Target

$220

2025-12-22

initiated

Reason

H.C. Wainwright assumed coverage of Spruce Biosciences with a Buy rating and $220 price target. The company is developing tralesinidase alfa enzyme replacement therapy for the treatment of Sanfilippo syndrome type B, the analyst tells investors in a research note. The firm sees potential for accelerated review. It believes TA-ERT could achieve peak sales of over $150M in the U.S. alone.

Leerink

Market Perform -> Outperform

upgrade

$160

2025-12-03

Reason

Leerink

Price Target

$160

2025-12-03

upgrade

Market Perform -> Outperform

Reason

Leerink upgraded Spruce Biosciences to Outperform from Market Perform with a $160 price target.

Leerink

Market Perform -> Outperform

upgrade

$160

2025-12-03

Reason

Leerink

Price Target

$160

2025-12-03

upgrade

Market Perform -> Outperform

Reason

Leerink upgraded Spruce Biosciences to Outperform from Market Perform with a $160 price target. After receiving Breakthrough Therapy Designation, the shares traded up to almost $200 in October 2025. After conducting a $50M PIPE, the stock has traded down to a more attractive valuation, the firm notes. Leerink is intrigued by the late-stage ERT - tralesinidase alfa - for mucopolysaccharidosis type IIIB, especially with shares trading lower than 1.0-time the firm's peak revenue opportunity.

Citizens JMP

Outperform

maintain

$254 -> $259

2025-11-11

Reason

Citizens JMP

Price Target

$254 -> $259

2025-11-11

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on Spruce Biosciences to $259 from $254 and keeps an Outperform rating on the shares. Spruce remains on track to submit its biologics license application for Tralesinidase Alfa Enzyme Replacement Therapy for Sanfilippo Syndrome Type B in 1Q26, the analyst tells investors in a research note. The firm is impressed with management's execution since its acquisition of TA-ERT.

Citizens JMP

Market Perform -> Outperform

upgrade

$254

2025-10-28

Reason

Citizens JMP

Price Target

$254

2025-10-28

upgrade

Market Perform -> Outperform

Reason

Citizens JMP upgraded Spruce Biosciences to Outperform from Market Perform with a $254 price target. The firm cites the company's acquisition of enzyme replacement therapy TA-ERT for Sanfilippo syndrome type B for the upgrade. TA-ERT has five-year data showing the ability to normalize heparin sulfate, the surrogate biomarker for accelerated approval, the analyst tells investors in a research note. Citizens models peak TAE-ERT sales of $170M, which it believes "could be conservative."

Leerink

Market Perform

maintain

$10 -> $160

2025-10-21

Reason

Leerink

Price Target

$10 -> $160

2025-10-21

maintain

Market Perform

Reason

Leerink raised the firm's price target on Spruce Biosciences to $160 from $10 and keeps a Market Perform rating on the shares. Spruce is executing a "significant strategic pivot" by shifting its focus from congenital adrenal hyperplasia to mucopolysaccharidosis type IIIB following a "disappointing update" on its former lead asset, tildacerfont, the analyst noted. The acquisition of tralesinidase alfa enzyme replacement therapy, or TA-ERT, for the pediatric neurodegenerative disorder MPS IIIB "flew under the radar" until the company was granted FDA Breakthrough Therapy Designation for TA-ERT, which is "catapulting the stock higher and allowing the company to secure much needed financing," the analyst added.

Valuation Metrics

The current forward P/E ratio for Spruce Biosciences Inc (SPRB.O) is -2.17, compared to its 5-year average forward P/E of -2.09. For a more detailed relative valuation and DCF analysis to assess Spruce Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.09

Current PE

-2.17

Overvalued PE

0.46

Undervalued PE

-4.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.55

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.89

Undervalued EV/EBITDA

-2.99

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

-63.66

Current PS

0.00

Overvalued PS

237.93

Undervalued PS

-365.25

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SPRB News & Events

Events Timeline

No data

News

7.5

01-08Newsfilter

Spruce Biosciences Secures $15 Million Loan to Support MPS IIIB Treatment Development

6.0

2025-12-23Benzinga

Cellectis SA Receives Buy Rating with $9 Price Target from Clear Street

5.0

2025-12-15Newsfilter

Spruce Biosciences Appoints Keli Walbert to Board, Aiming for TA-ERT Launch

People Also Watch

Frequently Asked Questions

What is Spruce Biosciences Inc (SPRB) stock price today?

The current price of SPRB is 79.99 USD — it has increased 8.53 % in the last trading day.

What is Spruce Biosciences Inc (SPRB)'s business?

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. The Company has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The Company's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.

What is the price predicton of SPRB Stock?

What is Spruce Biosciences Inc (SPRB)'s revenue for the last quarter?

Spruce Biosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What is Spruce Biosciences Inc (SPRB)'s earnings per share (EPS) for the last quarter?

Spruce Biosciences Inc. EPS for the last quarter amounts to -14.58 USD, decreased -7.43 % YoY.

What changes have occurred in the market's expectations for Spruce Biosciences Inc (SPRB)'s fundamentals?

How many employees does Spruce Biosciences Inc (SPRB). have?

Spruce Biosciences Inc (SPRB) has 21 emplpoyees as of January 10 2026.

What is Spruce Biosciences Inc (SPRB) market cap?

Today SPRB has the market capitalization of 85.62M USD.